<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: The purpose of this article is to review clinical issues related to the management of <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> in older patients with <z:mp ids='MP_0002055'>diabetes</z:mp> of long duration </plain></SENT>
<SENT sid="1" pm="."><plain>CONCLUSION: Older adults represent an extensive proportion of patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>Treatment goals need to be individualized to take into account comorbid conditions, life expectancy, <z:mp ids='MP_0002055'>diabetes</z:mp> complications, and the benefits of glycemic control </plain></SENT>
<SENT sid="3" pm="."><plain>For both older patients and especially those with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0000083'>renal insufficiency</z:hpo>, the most important drug-related adverse effect to avoid is <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo>, and avoidance of any severe <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> should be paramount </plain></SENT>
<SENT sid="4" pm="."><plain>Patients with long duration of <z:mp ids='MP_0002055'>diabetes</z:mp> are often treated with insulin </plain></SENT>
<SENT sid="5" pm="."><plain>Recent data show that glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi>-1 receptor <z:chebi fb="4" ids="48705">agonists</z:chebi> may be used in combination with insulin for patients not achieving glycemic goals, with reductions in the doses of insulin used and with a low risk of <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> and possible <z:hpo ids='HP_0001824'>weight loss</z:hpo> </plain></SENT>
</text></document>